ImmuneBridge

San Francisco, United States

ImmuneBridge is developing allogeneic immunotherapies for cancer.

$7.7M raised

Mar 2026

Seed

Top Investors

Insight PartnersGaingelsQuiet CapitalNFXPioneer Fund

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ImmuneBridge raised?

ImmuneBridge has raised $7.7M in total funding. The most recent round was Seed. The last funding was announced in March 2026.

Who are ImmuneBridge's investors?

ImmuneBridge's investors include Insight Partners, Gaingels, Quiet Capital, NFX, Pioneer Fund.

Where is ImmuneBridge headquartered?

ImmuneBridge is headquartered in San Francisco, United States.

What does ImmuneBridge do?

ImmuneBridge is developing allogeneic immunotherapies for cancer.

What stage is ImmuneBridge at?

ImmuneBridge is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 23, 2026.

MLA

"ImmuneBridge — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/immunebridge. Accessed June 3, 2026.

APA

VCBacked. (2026). ImmuneBridge — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/immunebridge

Wikipedia (cite web)

{{cite web |title=ImmuneBridge — Funding & Investors |url=https://www.vcbacked.co/company/immunebridge |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 23, 2026.